NCT02182869终止2 期
Safety Assessment of Cumulative Dose of Combivent® HFA-propelled Metered Dose Inhaler in Comparison to Combivent® CFC-propelled Metered Dose Inhaler. A Randomised, Double-blind, Active-controlled, Two-way Cross-over Study in COPD Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 7
- 主要终点
- Number of patients with clinically significant changes in electrocardiogram (ECG) parameters (ventricular rate, PQ, QRS, QT and QTc intervals)
研究概览
简要总结
Study to evaluate the safety of combivent delivered in two different formulations (hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC)) from a metered dose inhaler (MDI), using a cumulative dose response model in patients with COPD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients 40 years of age or older
- •A diagnosis of COPD as defined by American Thoracic Society (ATS) criteria. Patients must have relatively stable, moderate to severe airway obstruction with a baseline FEV 1 <=65% of predicted normal and FEV1/FVC >=70%.
- •A smoking history of more than ten pack-years. A pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year
- •Able to perform technical satisfactory pulmonary function test
- •Able to be trained in the proper use of a MDI
- •Having signed an informed consent from prior to participation in the trial
- •Affiliation to the French social security system or beneficiary of such a system
排除标准
- •Significant disease other than COPD. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
- •Clinical relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded
- •Serum glutamic oxaloacetic transaminase (SGOT) >80 IU/L; serum glutamic pyruvic transaminase (SGPT) >80IU/L, bilirubin >2.0mg/dL or creatinine >2.0mg/dL
- •Serum potassium level above or below the normal range
- •Total blood eosinophil count >=600/mm³
- •Recent history (i.e., one year or less) of myocardial infarction
- •Recent history (i.e., three years or less) of heart failure or any cardiac arrhythmia requiring drug therapy
- •History of cancer, other than treated basal cell carcinoma, within the last five years
- •History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis
- •History of thoracotomy with pulmonary resection. History or a thoracotomy for other reasons should be evaluated as per exclusion criteria no. 1
- •History of asthma, allergic rhinitis or atopy
- •History of or active alcohol or drug abuse
- •Known active tuberculosis
- •Upper respiratory tract infection or COPD exacerbation in the six weeks prior to screening visit or between the screening visit and visit 2
- •Known symptomatic prostatic hypertrophy or bladder neck obstruction
- •Known narrow-angle glaucoma
- •Current significant psychiatric disorders
- •Regular use of daytime oxygen therapy
- •Use of beta-blocker medications, mono-amine oxidase inhibitors or tricyclic antidepressants
- •Use of cromolyn sodium or nedocromil sodium
- •Use of antihistamines.
- •Use of oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose before screening visit or a change between the screening visit and visit2) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20mg every other day
- •Use of oral beta-adrenergics or long-acting beta-adrenergics such as salmeterol (Serevent®) and formoterol in the two weeks prior to the screening visit or between the screening visit and visit 2
- •Changes in the therapeutic plan within the last six weeks prior to the screening visit or between the screening visit and visit 2, excluding changes from long acting or oral beta-adrenergics to short acting inhaled beta-adrenergics for purposes of this trial
- •Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception
- •Known hypersensitivity to anti-cholinergic or beta-agonist drugs or any other component of either Combivent® formulations
- •Use of an investigational drug within one month or six half lives prior to the screening visit
- •Previous participation in this study
- •Patient deprived of their freedom by a judicial or administrative decision
- •Patient leaving in medical or social establishments
- •Patient hospitalized for mental disorder without his (her) consent
- •Patient under guardianship
- •Patient in emergency situations
研究组 & 干预措施
Combivent® HFA
Experimental
干预措施: Combivent® HFA inhalation aerosol (Drug)
Combivent® CFC
Active Comparator
干预措施: Combivent® CFC inhalation aerosol (Drug)
结局指标
主要结局
Number of patients with clinically significant changes in electrocardiogram (ECG) parameters (ventricular rate, PQ, QRS, QT and QTc intervals)
时间窗: Baseline, up to 8 days after last treatment day
Changes in intra ocular pressure (IOP)
时间窗: Baseline, up to 30 min after last drug administration
Changes in serum potassium levels
时间窗: Baseline, up to 180 min after last drug administration
Changes in serum glucose levels
时间窗: Baseline, up to 60 min after last drug administration
Number of patients with clinically significant changes in vital signs (blood pressure, puls rate, respiratory rate)
时间窗: Baseline, up to 8 days after last treatment day
Number of patients with clinically significant changes from baseline in clinical laboratory evaluations
时间窗: Baseline, 8 days after last treatment day
Number of patients with adverse events including paradoxical bronchospasm
时间窗: Up to 8 days after last treatment day
Number of patients with clinically significant changes from baseline in physical examination
时间窗: Baseline, 8 days after last treatment day
次要结局
- Change in FEV1 (forced expiratory volume in one second)(Baseline, up to 180 min after last drug administration)
- Change in FVC (forced vital capacity)(Baseline, up to 180 min after last drug administration)
研究者
相似试验
已完成
1 期
Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female SubjectsHealthyNCT02173678Boehringer Ingelheim12
终止
3 期
Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT02194205Boehringer Ingelheim360
已完成
3 期
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT01529632Novartis Pharmaceuticals193
已完成
1 期
The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin CaHealthy Male VolunteersNCT02250976Hanlim Pharm. Co., Ltd.41
Unknown
4 期
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular DegenerationAge-related Macular DegenerationNCT02802657Xiaodong Sun141